Cathie's Ark LogoCathie's Ark
Trading Floor Community IconFrom the Trading Floor:
Veracyte Inc Logo

ARKK Holdings of Veracyte (VCYT) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
December 3, 2021BUY430000.01%ARKK
December 2, 2021BUY396070.0088%ARKK
November 15, 2021BUY633000.0145%ARKK
November 12, 2021BUY402030.0093%ARKK
November 11, 2021BUY504770.0119%ARKK

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKGARKW$36.09
⚖️Weighting🧢Market Cap
0.95%$2.56b
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
3013.73
🏋️‍♀️Weight Rank Across All Funds🌏Country
31🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
5.84%
Description
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
Website
www.veracyte.com